A detailed history of Stephens Consulting, LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Stephens Consulting, LLC holds 80 shares of GILD stock, worth $5,472. This represents 0.0% of its overall portfolio holdings.

Number of Shares
80
Previous 80 -0.0%
Holding current value
$5,472
Previous $6.48 Million 9.58%
% of portfolio
0.0%
Previous 0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

Jan 19, 2023

SELL
$57.92 - $72.58 $868 - $1,088
-15 Reduced 15.79%
80 $4.76 Million
Q4 2021

Jan 19, 2023

BUY
$64.88 - $73.64 $6,163 - $6,995
95 New
95 $6.9 Million

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $85.7B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Stephens Consulting, LLC Portfolio

Follow Stephens Consulting, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Stephens Consulting, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Stephens Consulting, LLC with notifications on news.